GLP-1 Weight Loss Medications in Delaware
Access semaglutide and tirzepatide in Delaware through Medicaid, commercial insurance, and telehealth platforms.
Telehealth Prescribing
AllowedRestrictions
Delaware enacted SB 208 (2020) making telehealth flexibilities permanent. Providers must be licensed in Delaware. Audio-video and audio-only visits are permitted. Delaware requires commercial insurers to cover telehealth services at parity with in-person visits.
Prescribing Rules
GLP-1 medications can be prescribed via telehealth in Delaware without an in-person visit. Delaware does not restrict non-controlled medication prescribing through telehealth beyond standard documentation requirements.
Insurance Coverage
Medicaid Coverage
Prior Authorization
Major Insurers
Delaware expanded Medicaid in 2014. Delaware Medicaid covers GLP-1s for type 2 diabetes. Weight management coverage is expanding but typically requires prior authorization. Highmark BCBS dominates the commercial market in Delaware, covering the majority of commercially insured residents. Many Delawareans also access care through Philadelphia-area health systems.
Cost Breakdown
Brand Name
$900-$1350
per month, without insurance
Compounded
Available$175-$400
per month
Top Providers in Delaware
Ro
TelehealthServes Delaware residents with video consultations and compounded semaglutide delivery.
ChristianaCare Metabolic Health
In-PersonDelaware largest health system with weight management programs in Wilmington and Newark.
Sesame
TelehealthCash-pay GLP-1 consultations with transparent pricing for Delaware residents.
Delaware GLP-1 Access Overview
Delaware is the second-smallest state by area but benefits from proximity to major healthcare markets in Philadelphia and Baltimore. Many Delaware residents have access to Philadelphia-area obesity medicine specialists in addition to in-state options. ChristianaCare, the state largest health system, operates metabolic health programs that include GLP-1 prescribing. For those preferring convenience, telehealth platforms are widely available and popular.
Insurance Coverage in the First State
Highmark Blue Cross Blue Shield Delaware is the dominant commercial insurer. Highmark covers GLP-1 medications for type 2 diabetes and has expanded weight management coverage under select employer plans. Delaware Medicaid covers GLP-1s for diabetes, with ongoing evaluation of obesity-indication coverage. The state relatively small size means insurance market decisions by Highmark have an outsized impact on GLP-1 access for the commercially insured population.
Compounding and Cost Options
Delaware Board of Pharmacy oversees compounding pharmacies in the state. Both in-state compounding pharmacies and national 503B outsourcing facilities serve Delaware patients. The state proximity to Philadelphia means access to some of the largest compounding operations on the East Coast. Compounded semaglutide typically costs $175-$400/month compared to $900-$1,350 for brand-name formulations.
- Delaware patients can access Philadelphia-area compounding pharmacies
- National 503B facilities ship to Delaware with next-day delivery
- Telehealth platforms offer compounded semaglutide statewide
Frequently Asked Questions
Delaware Medicaid covers GLP-1 medications for type 2 diabetes. Weight management coverage is evolving and requires prior authorization with documented BMI and comorbidities.
Yes. Many Delawareans access Philadelphia-area health systems. However, you need a provider licensed in the state where care is delivered. Telehealth consultations require a Delaware-licensed provider if you are physically in Delaware.
Brand-name semaglutide costs $900-$1,350/month without insurance. Compounded semaglutide through telehealth platforms costs $175-$400/month.
Yes. Delaware has permanent telehealth parity laws. Multiple platforms serve Delaware residents, and prescriptions can be filled at local pharmacies or shipped directly.
Explore More
Related tools, medications, and guides